{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T21:38:22Z","timestamp":1791581902642,"version":"4.3.4"},"reference-count":90,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T00:00:00Z","timestamp":1710892800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA023100"],"award-info":[{"award-number":["P30 CA023100"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["5U01CA180888-08"],"award-info":[{"award-number":["5U01CA180888-08"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["5UG1CA233198-05"],"award-info":[{"award-number":["5UG1CA233198-05"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.ctrv.2024.102721","type":"journal-article","created":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T08:32:20Z","timestamp":1711009940000},"page":"102721","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"special_numbering":"C","title":["If it\u2019s a target, it\u2019s a pan-cancer target: Tissue is not the issue"],"prefix":"10.1016","volume":"125","author":[{"given":"Jacob J.","family":"Adashek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shumei","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason K.","family":"Sicklick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott M.","family":"Lippman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Razelle","family":"Kurzrock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2024.102721_b0005","unstructured":"https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-pembrolizumab-first-tissuesite-agnostic-indication."},{"key":"10.1016\/j.ctrv.2024.102721_b0010","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/annonc\/mdy539","article-title":"Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study","volume":"30","author":"Hong","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2024.102721_b0015","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s40265-018-1044-x","article-title":"Larotrectinib: first global approval","volume":"79","author":"Scott","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.ctrv.2024.102721_b0020","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1158\/2159-8290.CD-16-1237","article-title":"Safety and antitumor activity of the Multitargeted Pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two phase I trials (ALKA-372-001 and STARTRK-1)","volume":"7","author":"Drilon","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ctrv.2024.102721_b0025","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1158\/1078-0432.CCR-21-3597","article-title":"Updated integrated analysis of the efficacy and safety of entrectinib in patients with NTRK fusion-positive solid tumors","volume":"28","author":"Demetri","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2024.102721_b0030","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1007\/s40265-019-01177-y","article-title":"Entrectinib: first global approval","volume":"79","author":"Al-Salama","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.ctrv.2024.102721_b0035","unstructured":"https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-approves-pembrolizumab-adults-and-children-tmb-h-solid-tumors#:\u223c:text=On%20June%2016%2C%202020%2C%20the."},{"key":"10.1016\/j.ctrv.2024.102721_b0040","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1001\/jamaoncol.2020.4515","article-title":"Clinical activity and safety of the anti-programmed death 1 monoclonal antibody Dostarlimab for patients with recurrent or advanced mismatch repair-deficient endometrial cancer: a nonrandomized phase 1 clinical trial","volume":"6","author":"Oaknin","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ctrv.2024.102721_b0045","unstructured":"https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-dostarlimab-gxly-dmmr-advanced-solid-tumors."},{"key":"10.1016\/j.ctrv.2024.102721_b0050","unstructured":"https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-dabrafenib-combination-trametinib-unresectable-or-metastatic-solid."},{"key":"10.1016\/j.ctrv.2024.102721_b0055","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2024.102721_b0060","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2021-148103","article-title":"A phase 2 study of pemigatinib (FIGHT-203; INCB054828) in patients with myeloid\/lymphoid neoplasms (MLNs) with fibroblast growth factor receptor 1 (FGFR1) Rearrangement (MLN FGFR1)","volume":"138","author":"Gotlib","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2024.102721_b0065","unstructured":"https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-pemigatinib-relapsed-or-refractory-myeloidlymphoid-neoplasms-fgfr1-rearrangement."},{"key":"10.1016\/j.ctrv.2024.102721_b0070","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S1470-2045(22)00541-1","article-title":"Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1\/2, open-label, basket trial","volume":"23","author":"Subbiah","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2024.102721_b0075","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1038\/s41591-022-01984-z","article-title":"Accelerated approvals hit the target in precision oncology","volume":"28","author":"Subbiah","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2024.102721_b0080","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.trecan.2020.08.009","article-title":"From tissue-agnostic to N-of-one therapies: (R)Evolution of the Precision Paradigm","volume":"7","author":"Adashek","year":"2021","journal-title":"Trends Cancer"},{"key":"10.1016\/j.ctrv.2024.102721_b0085","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1056\/NEJMe2024831","article-title":"Selpercatinib aimed at RET-altered cancers","volume":"383","author":"Kurzrock","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2024.102721_b0090","doi-asserted-by":"crossref","DOI":"10.3390\/ph16040614","article-title":"Agnostic approvals in oncology: getting the right drug to the right patient with the right genomics","volume":"16","author":"Tateo","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.ctrv.2024.102721_b0095","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1038\/s43018-023-00676-y","article-title":"Considering molecular alterations as pan-cancer tissue-agnostic targets","volume":"4","author":"Adashek","year":"2023","journal-title":"Nat Cancer"},{"key":"10.1016\/j.ctrv.2024.102721_b0100","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/s43018-021-00204-w","article-title":"Missing the target in cancer therapy","volume":"2","author":"Adashek","year":"2021","journal-title":"Nat Cancer"},{"key":"10.1016\/j.ctrv.2024.102721_b0105","doi-asserted-by":"crossref","DOI":"10.1098\/rsob.150019","article-title":"From animaculum to single molecules: 300 years of the light microscope","volume":"5","author":"Wollman","year":"2015","journal-title":"Open Biol"},{"key":"10.1016\/j.ctrv.2024.102721_b0110","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1179\/his.2009.32.1.9","article-title":"Progress in the development of microscopical techniques for diagnostic pathology","volume":"32","author":"Titford","year":"2009","journal-title":"J Histotechnol"},{"key":"10.1016\/j.ctrv.2024.102721_b0115","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1126\/science.1058040","article-title":"The sequence of the human genome","volume":"291","author":"Venter","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.ctrv.2024.102721_b0120","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/35057062","article-title":"Initial sequencing and analysis of the human genome","volume":"409","author":"Lander","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2024.102721_b0125","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41698-023-00449-x","article-title":"ALK fusions in the pan-cancer setting: another tumor-agnostic target?","volume":"7","author":"Shreenivas","year":"2023","journal-title":"NPJ Precis Oncol"},{"key":"10.1016\/j.ctrv.2024.102721_b0130","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1214886","article-title":"Crizotinib versus chemotherapy in advanced ALK-positive lung cancer","volume":"368","author":"Shaw","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2024.102721_b0135","doi-asserted-by":"crossref","unstructured":"First Tissue-Agnostic Drug Approval Issued. Cancer Discov. 2017;7:656.","DOI":"10.1158\/2159-8290.CD-NB2017-078"},{"key":"10.1016\/j.ctrv.2024.102721_b0140","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of Larotrectinib in TRK fusion-positive cancers in adults and children","volume":"378","author":"Drilon","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2024.102721_b0145","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2017-CT060","article-title":"Abstract CT060: STARTRK-2: a global phase 2, open-label, basket study of entrectinib in patients with locally advanced or metastatic solid tumors harboring TRK, ROS1, or ALK gene fusions","volume":"77","author":"Drilon","year":"2017","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2024.102721_b0150","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1158\/1078-0432.CCR-16-1679","article-title":"RET aberrations in diverse cancers: next-generation sequencing of 4,871 patients","volume":"23","author":"Kato","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2024.102721_b0155","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1158\/1535-7163.MCT-21-0329","article-title":"Hallmarks of RET and co-occuring genomic alterations in RET-aberrant cancers","volume":"20","author":"Adashek","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ctrv.2024.102721_b0160","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1056\/NEJMoa2005653","article-title":"Efficacy of selpercatinib in RET fusion-positive non-small-cell lung cancer","volume":"383","author":"Drilon","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2024.102721_b0165","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1056\/NEJMoa2005651","article-title":"Efficacy of selpercatinib in RET-altered thyroid cancers","volume":"383","author":"Wirth","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2024.102721_b0170","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.trecan.2021.07.003","article-title":"Precision therapy for RET-altered cancers with RET inhibitors","volume":"7","author":"Thein","year":"2021","journal-title":"Trends Cancer"},{"key":"10.1016\/j.ctrv.2024.102721_b0175","article-title":"Analysis of NTRK alterations in Pan-cancer adult and pediatric malignancies: implications for NTRK-Targeted therapeutics. JCO Precis","volume":"2018","author":"Okamura","year":"2018","journal-title":"Oncol"},{"key":"10.1016\/j.ctrv.2024.102721_b0180","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1177\/1535370220959657","article-title":"Prevalence of class I-III BRAF mutations among 114,662 cancer patients in a large genomic database","volume":"246","author":"Owsley","year":"2021","journal-title":"Exp Biol Med (Maywood)"},{"key":"10.1016\/j.ctrv.2024.102721_b0185","article-title":"Landscape of microsatellite instability across 39 cancer types. JCO Precis","volume":"2017","author":"Bonneville","year":"2017","journal-title":"Oncol"},{"key":"10.1016\/j.ctrv.2024.102721_b0190","doi-asserted-by":"crossref","first-page":"e2025109","DOI":"10.1001\/jamanetworkopen.2020.25109","article-title":"Prevalence of high tumor mutational burden and association with survival in patients with less common solid tumors","volume":"3","author":"Shao","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ctrv.2024.102721_b0195","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1158\/2326-6066.CIR-19-0149","article-title":"Microsatellite-stable tumors with high mutational burden benefit from immunotherapy","volume":"7","author":"Goodman","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.ctrv.2024.102721_b0200","doi-asserted-by":"crossref","first-page":"7546","DOI":"10.1128\/MCB.25.17.7546-7556.2005","article-title":"Mechanism of von hippel-Lindau protein-mediated suppression of nuclear factor kappa B activity","volume":"25","author":"An","year":"2005","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.ctrv.2024.102721_b0205","unstructured":"https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-belzutifan-cancers-associated-von-hippel-lindau-disease."},{"key":"10.1016\/j.ctrv.2024.102721_b0210","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1056\/NEJMoa2103425","article-title":"Belzutifan for renal cell Carcinoma in von hippel-Lindau disease","volume":"385","author":"Jonasch","year":"2021","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"10.1016\/j.ctrv.2024.102721_b0215","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1038\/ejhg.2016.93","article-title":"The biological effects and clinical implications of BRCA mutations: where do we go from here?","volume":"24","author":"Stoppa-Lyonnet","year":"2016","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.ctrv.2024.102721_b0220","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1093\/oncolo\/oyab053","article-title":"Homologous recombination deficiency: concepts, definitions, and assays","volume":"27","author":"Stewart","year":"2022","journal-title":"Oncologist"},{"key":"10.1016\/j.ctrv.2024.102721_b0225","unstructured":"Casaubon JT, Kashyap S, Regan JP. BRCA1 and BRCA2 Mutations. StatPearls. Treasure Island (FL) ineligible companies. Disclosure: Sarang Kashyap declares no relevant financial relationships with ineligible companies. Disclosure: John-Paul Regan declares no relevant financial relationships with ineligible companies.2023."},{"key":"10.1016\/j.ctrv.2024.102721_b0230","article-title":"Clinical limitations and recent attempts to overcome them","volume":"23","author":"Kim","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ctrv.2024.102721_b0235","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s10555-015-9552-6","article-title":"HER2 expression status in diverse cancers: review of results from 37,992 patients","volume":"34","author":"Yan","year":"2015","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.ctrv.2024.102721_b0240","doi-asserted-by":"crossref","first-page":"e2200604","DOI":"10.1200\/PO.22.00604","article-title":"Comprehensive analysis of human epidermal growth factor receptor 2 through DNA, mRNA, and protein in diverse malignancies","volume":"7","author":"Shayeb","year":"2023","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.ctrv.2024.102721_b0245","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.ctrv.2014.02.008","article-title":"HER2 aberrations in cancer: implications for therapy","volume":"40","author":"Yan","year":"2014","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ctrv.2024.102721_b0250","article-title":"Targeting ERBB2 (HER2) amplification identified by next-generation sequencing in patients with advanced or metastatic solid tumors beyond conventional indications. JCO Precis","volume":"3","author":"Dumbrava","year":"2019","journal-title":"Oncol"},{"key":"10.1016\/j.ctrv.2024.102721_b0255","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.ccell.2020.03.003","article-title":"Pan-cancer landscape and analysis of ERBB2 mutations identifies poziotinib as a clinically active inhibitor and enhancer of T-DM1 activity","volume":"37","author":"Robichaux","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ctrv.2024.102721_b0260","doi-asserted-by":"crossref","first-page":"e1303","DOI":"10.1634\/theoncologist.2018-0845","article-title":"Emergence of ERBB2 mutation as a Biomarker and an actionable Target in solid cancers","volume":"24","author":"Subramanian","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.ctrv.2024.102721_b0265","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: Primary results from the DESTINY-PanTumor02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102721_b0270","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2024.102721_b0275","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa2112431","article-title":"Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer","volume":"386","author":"Li","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2024.102721_b0280","unstructured":"https:\/\/www.drugs.com\/history\/enhertu.html."},{"key":"10.1016\/j.ctrv.2024.102721_b0285","unstructured":"https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-tucatinib-trastuzumab-colorectal-cancer."},{"key":"10.1016\/j.ctrv.2024.102721_b0290","doi-asserted-by":"crossref","first-page":"4966","DOI":"10.1158\/1078-0432.CCR-19-0160","article-title":"Detection of NRG1 gene fusions in solid tumors","volume":"25","author":"Jonna","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2024.102721_b0295","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1158\/2159-8290.CD-21-1119","article-title":"Zenocutuzumab, a HER2xHER3 bispecific antibody, is effective therapy for tumors driven by NRG1 gene Rearrangements","volume":"12","author":"Schram","year":"2022","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ctrv.2024.102721_b0300","unstructured":"https:\/\/www.cbioportal.org\/results\/comparison?cancer_study_list=msk_impact_2017&Z_SCORE_THRESHOLD=2.0&RPPA_SCORE_THRESHOLD=2.0&profileFilter=mutations%2Cstructural_variants%2Ccna&case_set_id=msk_impact_2017_all&gene_list=KIT&geneset_list=%20&tab_index=tab_visualize&Action=Submit&comparison_subtab=survival."},{"key":"10.1016\/j.ctrv.2024.102721_b0305","unstructured":"https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-sotorasib-kras-g12c-mutated-nsclc."},{"key":"10.1016\/j.ctrv.2024.102721_b0310","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s40265-023-01839-y","article-title":"First approval","volume":"83","author":"Adagrasib","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.ctrv.2024.102721_b0315","unstructured":"https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-avapritinib-advanced-systemic-mastocytosis."},{"key":"10.1016\/j.ctrv.2024.102721_b0320","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1200\/JCO.20.03245","article-title":"Inhibition of KIT tyrosine kinase activity: two decades after the first approval","volume":"39","author":"Klug","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102721_b0325","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1158\/1078-0432.CCR-20-3761","article-title":"Concomitant MEK and cyclin gene alterations: implications for response to Targeted therapeutics","volume":"27","author":"Kato","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2024.102721_b0330","doi-asserted-by":"crossref","first-page":"e2100245","DOI":"10.1200\/PO.21.00245","article-title":"Landscape of KRAS(G12C), associated genomic alterations, and Interrelation with immuno-oncology Biomarkers in KRAS-mutated cancers","volume":"6","author":"Salem","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.ctrv.2024.102721_b0335","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1056\/NEJMoa2303810","article-title":"Single-agent Divarasib (GDC-6036) in solid tumors with a KRAS G12C mutation","volume":"389","author":"Sacher","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2024.102721_b0340","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1007\/s40265-018-0978-3","article-title":"First global approval","volume":"78","author":"Ivosidenib","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.ctrv.2024.102721_b0345","article-title":"Metabolic adaptations in cancers expressing isocitrate dehydrogenase mutations","volume":"2","author":"Hvinden","year":"2021","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.ctrv.2024.102721_b0350","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/s41571-021-00521-0","article-title":"The implications of IDH mutations for cancer development and therapy","volume":"18","author":"Pirozzi","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102721_b0355","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1056\/NEJMoa2304194","article-title":"Vorasidenib in IDH1- or IDH2-mutant low-grade glioma","volume":"389","author":"Mellinghoff","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2024.102721_b0360","unstructured":"https:\/\/meetings.asco.org\/abstracts-presentations\/229373\/slides."},{"key":"10.1016\/j.ctrv.2024.102721_b0365","doi-asserted-by":"crossref","DOI":"10.1158\/2159-8290.CD-23-1138","article-title":"Sotorasib is a pan-RASG12C inhibitor capable of driving clinical response in NRASG12C cancers","author":"Rubinson","year":"2024","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ctrv.2024.102721_b0370","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a009209","article-title":"MET: a critical player in tumorigenesis and therapeutic target","volume":"5","author":"Graveel","year":"2013","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"10.1016\/j.ctrv.2024.102721_b0375","doi-asserted-by":"crossref","first-page":"e2300174","DOI":"10.1200\/PO.23.00174","article-title":"Exceptional response to crizotinib with subsequent response to cabozantinib in metastatic, ROS1-GOPC fusion-mutated breast cancer","volume":"7","author":"O'Neil","year":"2023","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.ctrv.2024.102721_b0380","doi-asserted-by":"crossref","first-page":"e82","DOI":"10.1093\/oncolo\/oyac180","article-title":"Comprehensive landscape of cyclin pathway gene alterations and co-occurrence with FGF\/FGFR aberrations across Urinary Tract tumors","volume":"28","author":"Jardim","year":"2023","journal-title":"Oncologist"},{"key":"10.1016\/j.ctrv.2024.102721_b0385","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100647","article-title":"Targeting the FGF\/FGFR axis and its co-alteration allies","volume":"7","author":"Uehara","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.ctrv.2024.102721_b0390","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1182\/blood-2016-07-418434","article-title":"BRAF V600E mutation in hairy cell leukemia: from bench to bedside","volume":"128","author":"Falini","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2024.102721_b0395","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1056\/NEJMoa1506583","article-title":"Targeting mutant BRAF in relapsed or Refractory hairy-cell leukemia","volume":"373","author":"Tiacci","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2024.102721_b0400","doi-asserted-by":"crossref","unstructured":"Patel H, Yacoub N, Mishra R, White A, Long Y, Alanazi S, et al. Current Advances in the Treatment of BRAF-Mutant Melanoma. Cancers (Basel). 2020;12.","DOI":"10.3390\/cancers12020482"},{"key":"10.1016\/j.ctrv.2024.102721_b0405","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1158\/1535-7163.MCT-15-0643","article-title":"Genomically driven tumors and actionability across histologies: BRAF-mutant cancers as a Paradigm","volume":"15","author":"Turski","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ctrv.2024.102721_b0410","unstructured":"https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-encorafenib-combination-cetuximab-metastatic-colorectal-cancer-braf-v600e-mutation."},{"key":"10.1016\/j.ctrv.2024.102721_b0415","doi-asserted-by":"crossref","first-page":"e404770","DOI":"10.1200\/EDBK_404770","article-title":"Expanding the benefit: dabrafenib\/trametinib as tissue-agnostic therapy for BRAF V600E-positive adult and pediatric solid tumors","volume":"43","author":"Gouda","year":"2023","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.ctrv.2024.102721_b0420","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/s41591-019-0424-4","article-title":"Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial","volume":"25","author":"Rodon","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2024.102721_b0425","doi-asserted-by":"crossref","first-page":"4965","DOI":"10.1038\/s41467-020-18613-3","article-title":"Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-one strategy","volume":"11","author":"Kato","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.ctrv.2024.102721_b0430","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s13073-021-00969-w","article-title":"Molecular profiling of advanced malignancies guides first-line N-of-1 treatments in the I-PREDICT treatment-naive study","volume":"13","author":"Sicklick","year":"2021","journal-title":"Genome Med"},{"key":"10.1016\/j.ctrv.2024.102721_b0435","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15030818","article-title":"Implementing HRD testing in routine clinical Practice on patients with Primary high-grade advanced Ovarian cancer","volume":"15","author":"Heitz","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ctrv.2024.102721_b0440","article-title":"Signed in blood: circulating tumor DNA in cancer diagnosis","volume":"13","author":"Adashek","year":"2021","journal-title":"Treatment and Screening Cancers (Basel)"},{"key":"10.1016\/j.ctrv.2024.102721_b0445","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djx118","article-title":"Concordance of circulating tumor DNA and matched metastatic tissue biopsy in prostate cancer","volume":"109","author":"Wyatt","year":"2017","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ctrv.2024.102721_b0450","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s13045-019-0824-4","article-title":"Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer","volume":"12","author":"Patel","year":"2019","journal-title":"J Hematol Oncol"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737224000483?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737224000483?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T08:13:03Z","timestamp":1713946383000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737224000483"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":90,"alternative-id":["S0305737224000483"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2024.102721","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"If it\u2019s a target, it\u2019s a pan-cancer target: Tissue is not the issue","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2024.102721","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102721"}}